PMID- 24996227
OWN - NLM
STAT- MEDLINE
DCOM- 20141209
LR  - 20220311
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 14
DP  - 2014 Jul 5
TI  - Quality of life in purely ocular myasthenia in Japan.
PG  - 142
LID - 10.1186/1471-2377-14-142 [doi]
AB  - BACKGROUND: Since there has been no conclusive evidence regarding the treatment 
      of ocular myasthenia, treatment guidelines were recently issued by the European 
      Federation of Neurological Societies/European Neurological Society (EFNS/ENS). 
      However, the therapeutic outcomes concerning the quality-of-life (QOL) of 
      patients with ocular myasthenia are not yet fully understood. METHODS: We 
      investigated the therapeutic outcomes of patients with purely ocular myasthenia 
      in a multicenter cross-sectional survey in Japan. To evaluate the severity of 
      ocular symptoms, we used the ocular-quantitative MG (QMG) score advocated by 
      Myasthenia Gravis Foundation of America. We used the Japanese translated version 
      of the MG-QOL15, a self-appraised scoring system. RESULTS: Of 607 myasthenia 
      gravis (MG) patients with an observation-duration of illness >/= 2 years, the cases 
      of 123 patients (20%) were limited to ocular muscles (purely ocular myasthenia). 
      During the entire clinical course, 81 patients experienced both ptosis and 
      diplopia, 36 had ptosis alone, and six had diplopia alone. Acetyl-cholinesterase 
      inhibitors and prednisolone were used in 98 and 52 patients, respectively. 
      Treatment improved ocular symptoms, with the mean reduction in ocular-QMG score 
      of 2.3 +/- 1.8 points. However, 47 patients (38%) failed to gain minimal 
      manifestation or a better status. Patients with unfavorable outcomes also 
      self-reported severe QOL impairment. Multivariate analyses showed that the 
      pretreatment ocular-QMG score was associated with unfavorable outcomes, but not 
      associated with the patient's QOL. CONCLUSION: A treatment strategy designed in 
      accord with a patient's ocular presentation must be considered in order to 
      improve ocular symptoms and the patient's QOL.
FAU - Suzuki, Shigeaki
AU  - Suzuki S
AD  - Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, 
      Shinjuku-ku, Tokyo 160-8582, Japan. sgsuzuki@z3.keio.jp.
FAU - Murai, Hiroyuki
AU  - Murai H
FAU - Imai, Tomihiro
AU  - Imai T
FAU - Nagane, Yuriko
AU  - Nagane Y
FAU - Masuda, Masayuki
AU  - Masuda M
FAU - Tsuda, Emiko
AU  - Tsuda E
FAU - Konno, Shingo
AU  - Konno S
FAU - Oji, Satoru
AU  - Oji S
FAU - Nakane, Shunya
AU  - Nakane S
FAU - Motomura, Masakatsu
AU  - Motomura M
FAU - Suzuki, Norihiro
AU  - Suzuki N
FAU - Utsugisawa, Kimiaki
AU  - Utsugisawa K
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140705
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cholinesterase Inhibitors)
RN  - 9PHQ9Y1OLM (Prednisolone)
SB  - IM
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Cholinesterase Inhibitors/therapeutic use
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Myasthenia Gravis/*complications/*drug therapy
MH  - Prednisolone/therapeutic use
MH  - *Quality of Life
PMC - PMC4088302
EDAT- 2014/07/06 06:00
MHDA- 2014/12/15 06:00
PMCR- 2014/07/05
CRDT- 2014/07/06 06:00
PHST- 2014/04/14 00:00 [received]
PHST- 2014/07/01 00:00 [accepted]
PHST- 2014/07/06 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
PHST- 2014/07/05 00:00 [pmc-release]
AID - 1471-2377-14-142 [pii]
AID - 10.1186/1471-2377-14-142 [doi]
PST - epublish
SO  - BMC Neurol. 2014 Jul 5;14:142. doi: 10.1186/1471-2377-14-142.